Alicia M Fry1, Doli Goswami2, Kamrun Nahar2, Amina T Sharmin2, Mustafizur Rahman2, Larisa Gubareva3, Alma Trujillo3, John Barnes3, Tasnim Azim2, Joseph Bresee3, Stephen P Luby4, W Abdullah Brooks5. 1. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: afry@cdc.gov. 2. International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh. 3. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Stanford University, Stanford, CA, USA. 5. International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MA, USA.
Abstract
BACKGROUND: Antiviral drugs are a proposed medical intervention to reduce household transmission of influenza viruses. In a previously described randomised, placebo-controlled trial in Dhaka, Bangladesh, we showed that oseltamivir treatment of index patients was able to reduce influenza symptom duration and virus shedding. In a further analysis that is part of the same study, we aimed to assess efficacy of oseltamivir to reduce secondary household illnesses in the same cohort. METHODS: In this double-blind oseltamivir efficacy trial, we identified index patients aged older than 1 year through surveillance of households in Dhaka, Bangladesh. We randomly allocated eligible patients (1:1) to receive oseltamivir or placebo twice-daily for 5 days, and we stratified them by enrolment 48 h versus 48-120 h since illness onset. Participants provided nasal wash specimens at enrolment and 2, 4, and 7 days after enrolment and were visited daily by a research assistant to record symptoms, both in index patients and in household members. For this part of the study, household members were asked to give respiratory specimens for influenza PCR testing. Our primary outcomes were household secondary illness and PCR-confirmed influenza virus infection, assessed in household members of all randomly allocated index patients. This trial is registered with ClinicalTrials.gov, number NCT00707941. FINDINGS: From May 11, 2008, to Dec 31, 2010, we enrolled 1190 index patients with 4694 household members. 592 patients were allocated to placebo (2292 household members) and 598 to oseltamivir (2402 household members). Household secondary illness was lower in the oseltamivir group (196 [8%] influenza cases) than in the placebo group (233 [10%]; odds ratio [OR] 0·77, 95% CI 0·60-0·98, p=0·031). PCR-confirmed influenza virus infection did not differ between the placebo (103 [5%]) and oseltamivir groups (92 [4%]; 0·84, 0·59-1·19, p=0·319); however, only 243 (57%) of ill household members gave a specimen for analysis. INTERPRETATION: In a crowded, low income setting, oseltamivir treatment of index patients resulted in a small reduction of secondary influenza in their households. Even this slight reduction, in the setting of widespread antiviral use during a community influenza outbreak, might result in reductions in overall disease burden. FUNDING: Centers for Disease Control and Prevention (in an agreement with the International Centre for Diarrhoeal Disease Research, Bangladesh).
RCT Entities:
BACKGROUND: Antiviral drugs are a proposed medical intervention to reduce household transmission of influenza viruses. In a previously described randomised, placebo-controlled trial in Dhaka, Bangladesh, we showed that oseltamivir treatment of index patients was able to reduce influenza symptom duration and virus shedding. In a further analysis that is part of the same study, we aimed to assess efficacy of oseltamivir to reduce secondary household illnesses in the same cohort. METHODS: In this double-blind oseltamivir efficacy trial, we identified index patients aged older than 1 year through surveillance of households in Dhaka, Bangladesh. We randomly allocated eligible patients (1:1) to receive oseltamivir or placebo twice-daily for 5 days, and we stratified them by enrolment 48 h versus 48-120 h since illness onset. Participants provided nasal wash specimens at enrolment and 2, 4, and 7 days after enrolment and were visited daily by a research assistant to record symptoms, both in index patients and in household members. For this part of the study, household members were asked to give respiratory specimens for influenza PCR testing. Our primary outcomes were household secondary illness and PCR-confirmed influenza virus infection, assessed in household members of all randomly allocated index patients. This trial is registered with ClinicalTrials.gov, number NCT00707941. FINDINGS: From May 11, 2008, to Dec 31, 2010, we enrolled 1190 index patients with 4694 household members. 592 patients were allocated to placebo (2292 household members) and 598 to oseltamivir (2402 household members). Household secondary illness was lower in the oseltamivir group (196 [8%] influenza cases) than in the placebo group (233 [10%]; odds ratio [OR] 0·77, 95% CI 0·60-0·98, p=0·031). PCR-confirmed influenza virus infection did not differ between the placebo (103 [5%]) and oseltamivir groups (92 [4%]; 0·84, 0·59-1·19, p=0·319); however, only 243 (57%) of ill household members gave a specimen for analysis. INTERPRETATION: In a crowded, low income setting, oseltamivir treatment of index patients resulted in a small reduction of secondary influenza in their households. Even this slight reduction, in the setting of widespread antiviral use during a community influenza outbreak, might result in reductions in overall disease burden. FUNDING: Centers for Disease Control and Prevention (in an agreement with the International Centre for Diarrhoeal Disease Research, Bangladesh).
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Kira L Newman; Julia H Rogers; Denise McCulloch; Naomi Wilcox; Janet A Englund; Michael Boeckh; Timothy M Uyeki; Michael L Jackson; Lea Starita; James P Hughes; Helen Y Chu Journal: Trials Date: 2020-11-23 Impact factor: 2.279
Authors: Leo Yi Yang Lee; Jie Zhou; Rebecca Frise; Daniel H Goldhill; Paulina Koszalka; Edin J Mifsud; Kaoru Baba; Takahiro Noda; Yoshinori Ando; Kenji Sato; Aoe-Ishikawa Yuki; Takao Shishido; Takeki Uehara; Steffen Wildum; Elke Zwanziger; Neil Collinson; Klaus Kuhlbusch; Barry Clinch; Aeron C Hurt; Wendy S Barclay Journal: PLoS Pathog Date: 2020-04-15 Impact factor: 6.823
Authors: Alpana Waghmare; Elizabeth M Krantz; Subhasish Baral; Emma Vasquez; Tillie Loeffelholz; E Lisa Chung; Urvashi Pandey; Jane Kuypers; Elizabeth R Duke; Keith R Jerome; Alexander L Greninger; Daniel B Reeves; Florian Hladik; E Fabian Cardozo-Ojeda; Michael Boeckh; Joshua T Schiffer Journal: medRxiv Date: 2020-04-06
Authors: Alpana Waghmare; Elizabeth M Krantz; Subhasish Baral; Emma Vasquez; Tillie Loeffelholz; E Lisa Chung; Urvashi Pandey; Jane Kuypers; Elizabeth R Duke; Keith R Jerome; Alexander L Greninger; Daniel B Reeves; Florian Hladik; E Fabian Cardozo-Ojeda; Michael Boeckh; Joshua T Schiffer Journal: J Infect Dis Date: 2020-07-25 Impact factor: 7.759